Impact of drug therapy on long-term prognosis in patients with ischemic chronic heart failure with reduced ejection fraction and renal dysfunction

Despite the achievements of recent decades, chronic heart failure (CHF) is one of the most widespread and steadily progressive disease which accompanied by high mortality. Aim. To investigate the effect of combined drug therapy for long-term prognosis in patients with ischemic heart failure with...

Full description

Bibliographic Details
Main Author: D. A. Lashkul
Format: Article
Language:English
Published: Zaporozhye State Medical University 2016-08-01
Series:Zaporožskij Medicinskij Žurnal
Subjects:
Online Access:http://zmj.zsmu.edu.ua/article/view/79758/77460
id doaj-b48c902696de49208e65e03e7da3740b
record_format Article
spelling doaj-b48c902696de49208e65e03e7da3740b2020-11-25T00:42:49ZengZaporozhye State Medical UniversityZaporožskij Medicinskij Žurnal2306-41452310-12102016-08-014343910.14739/2310-1210.2016.4.79758Impact of drug therapy on long-term prognosis in patients with ischemic chronic heart failure with reduced ejection fraction and renal dysfunctionD. A. LashkulDespite the achievements of recent decades, chronic heart failure (CHF) is one of the most widespread and steadily progressive disease which accompanied by high mortality. Aim. To investigate the effect of combined drug therapy for long-term prognosis in patients with ischemic heart failure with reduced ejection fraction of left ventricle and renal dysfunction. Materials and methods. The study involved 140 patients (114 (81.4%) men) with ischemic chronic heart failure; average age was 60 [54.5-68] years. Therapy included: ACE inhibitors/ARBs (90%), beta blockers (94.3%), diuretics (87.8%), statins (84.3%), mineralocorticoid receptor antagonists (75%), antiplatelet agents (70.7%), calcium antagonists (14.3%), amiodarone (18.6%), ivabradin (15%). The cumulative survival curves were constructed by the Kaplan-Meier method using and groups were compared with the log-rank test. Results. In our study it has been established that statins inclusion in the therapy of patients with ischemic heart failure with reduced ejection fraction of left ventricle and renal dysfunction reduces the risk of cumulative endpoint by 51% (hazard ratio (HR) 0.49, 95% confidence interval (CI) 0.26 -0.91, p=0.02), prescription of trimetazidine - by 43% (HR 0.57, 95% CI 0.34-0.95, p=0.03), nitrates - by 47% (HR 0.53; 95% CI 0.31-0.89, p=0.01). Inclusion of mineralocorticoid receptor antagonists increased number of cardiovascular events during three years of monitoring (HR 1.88, 95% CI 1.21-2.94, p=0.005). Inclusion of aspirin reduced the risk of SCD by 75% (HR 0.25, 95% CI 0.12-0.53, p=0.0004). Inclusion of nitrates by 55% (HR 0.45, 95% CI 0.23-0.89, p=0.02) and statins by 68% (HR 0.32, 95% CI 0.14-0.72; p=0.006) reduced hospitalization. Conclusion. Based on three-year monitoring results of ischemic heart failure patients with reduced ejection fraction and renal dysfunction it has been found that the inclusion of statins, nitrates, trimetazidine to standard therapy was associated with reduced risk of cumulative endpoint and hospitalization caused by heart failure decompensation. http://zmj.zsmu.edu.ua/article/view/79758/77460heart failuredrug therapykidney
collection DOAJ
language English
format Article
sources DOAJ
author D. A. Lashkul
spellingShingle D. A. Lashkul
Impact of drug therapy on long-term prognosis in patients with ischemic chronic heart failure with reduced ejection fraction and renal dysfunction
Zaporožskij Medicinskij Žurnal
heart failure
drug therapy
kidney
author_facet D. A. Lashkul
author_sort D. A. Lashkul
title Impact of drug therapy on long-term prognosis in patients with ischemic chronic heart failure with reduced ejection fraction and renal dysfunction
title_short Impact of drug therapy on long-term prognosis in patients with ischemic chronic heart failure with reduced ejection fraction and renal dysfunction
title_full Impact of drug therapy on long-term prognosis in patients with ischemic chronic heart failure with reduced ejection fraction and renal dysfunction
title_fullStr Impact of drug therapy on long-term prognosis in patients with ischemic chronic heart failure with reduced ejection fraction and renal dysfunction
title_full_unstemmed Impact of drug therapy on long-term prognosis in patients with ischemic chronic heart failure with reduced ejection fraction and renal dysfunction
title_sort impact of drug therapy on long-term prognosis in patients with ischemic chronic heart failure with reduced ejection fraction and renal dysfunction
publisher Zaporozhye State Medical University
series Zaporožskij Medicinskij Žurnal
issn 2306-4145
2310-1210
publishDate 2016-08-01
description Despite the achievements of recent decades, chronic heart failure (CHF) is one of the most widespread and steadily progressive disease which accompanied by high mortality. Aim. To investigate the effect of combined drug therapy for long-term prognosis in patients with ischemic heart failure with reduced ejection fraction of left ventricle and renal dysfunction. Materials and methods. The study involved 140 patients (114 (81.4%) men) with ischemic chronic heart failure; average age was 60 [54.5-68] years. Therapy included: ACE inhibitors/ARBs (90%), beta blockers (94.3%), diuretics (87.8%), statins (84.3%), mineralocorticoid receptor antagonists (75%), antiplatelet agents (70.7%), calcium antagonists (14.3%), amiodarone (18.6%), ivabradin (15%). The cumulative survival curves were constructed by the Kaplan-Meier method using and groups were compared with the log-rank test. Results. In our study it has been established that statins inclusion in the therapy of patients with ischemic heart failure with reduced ejection fraction of left ventricle and renal dysfunction reduces the risk of cumulative endpoint by 51% (hazard ratio (HR) 0.49, 95% confidence interval (CI) 0.26 -0.91, p=0.02), prescription of trimetazidine - by 43% (HR 0.57, 95% CI 0.34-0.95, p=0.03), nitrates - by 47% (HR 0.53; 95% CI 0.31-0.89, p=0.01). Inclusion of mineralocorticoid receptor antagonists increased number of cardiovascular events during three years of monitoring (HR 1.88, 95% CI 1.21-2.94, p=0.005). Inclusion of aspirin reduced the risk of SCD by 75% (HR 0.25, 95% CI 0.12-0.53, p=0.0004). Inclusion of nitrates by 55% (HR 0.45, 95% CI 0.23-0.89, p=0.02) and statins by 68% (HR 0.32, 95% CI 0.14-0.72; p=0.006) reduced hospitalization. Conclusion. Based on three-year monitoring results of ischemic heart failure patients with reduced ejection fraction and renal dysfunction it has been found that the inclusion of statins, nitrates, trimetazidine to standard therapy was associated with reduced risk of cumulative endpoint and hospitalization caused by heart failure decompensation.
topic heart failure
drug therapy
kidney
url http://zmj.zsmu.edu.ua/article/view/79758/77460
work_keys_str_mv AT dalashkul impactofdrugtherapyonlongtermprognosisinpatientswithischemicchronicheartfailurewithreducedejectionfractionandrenaldysfunction
_version_ 1725280123096137728